GGrantIndex
Sort

23,748 grants matching melanoma

Multimeric Ligands for Targeting Melanoma

$636,070
Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2008 · CA

Melanocyte PDL1 control of UVB-induced IFN-I

$635,946
Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2024 · CA

Melanocyte PDL1 control of UVB-induced IFN-I

$635,946
Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2025 · CA

Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer

$635,854
Michelle S Bradbury · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations

$635,757
Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2023 · CA

Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.

$635,587
Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2018 · CA

Impact of mutation burden on cancer growth and the immune landscape

$635,557
Shridar Ganesan · Rutgers Biomedical And Health Sciences · R01 · FY2023 · CA

Rational Approaches to Melanoma Therapy

$635,508
Jessie Villanueva · Wistar Institute · U54 · FY2023 · CA

Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA

$635,296
Douglas C Wallace · Children'S Hosp Of Philadelphia · R01 · FY2025 · CA

Validating and Characterizing a New Melanoma Therapeutic Target

$635,068
Sara A Courtneidge · Oregon Health & Science University · R01 · FY2018 · CA

Yale Skin Diseases Research Core Center

$635,065
Robert E. Tigelaar · Yale University · P30 · FY2008 · AR

Molecular Diagnostics Core Laboratory

$635,058
Mark Raffeld · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA

Yale Skin Diseases Research Core Center

$635,034
Robert E. Tigelaar · Yale University · P30 · FY2007 · AR

Cancer Genetics of Long Telomere Syndromes

$635,033
Mary Y. Armanios · Johns Hopkins University · R01 · FY2025 · CA

Combating melanoma resistance by targeting ABL1/2

$634,772
Rina Plattner · University Of Kentucky · R01 · FY2022 · CA

(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy

$634,715
Elad Ziv · University Of California, San Francisco · R01 · FY2019 · CA

Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer

$634,454
Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2021 · CA

Regulatory T cells in cancer therapy

$634,434
Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Regulatory T cells in cancer therapy

$634,296
Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2023 · CA

Gamma delta T cell based melanoma therapies

$634,246
Xiaowei Xu · University Of Pennsylvania · R01 · FY2025 · CA

Optimizing TCR-CD3 signaling for immunotherapy of cancer

$634,208
Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2025 · CA

Immune dysregulation mechanisms of persistent post-COVID19 olfactory dysfunction

$634,157
Lora Bankova · Brigham And Women'S Hospital · R01 · FY2025 · DC

Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research

$634,033
Rebecca S Crowley · University Of Pittsburgh At Pittsburgh · U24 · FY2016 · CA

Redox imaging for breast cancer prognosis

$634,016
Lin Z Li · University Of Pennsylvania · R01 · FY2017 · CA

Regulation of resistance to CDK4/6 inhibitor in breast cancer

$633,959
Wenge Zhu · George Washington University · R01 · FY2025 · CA